Activity of two different triazoles in a murine model of paracoccidioidomycosis.

Abstract

A new orally absorbable triazole (Schering 39304) with a long serum half-life in man (60 hours), was tried in a murine model of progressive paracoccidioidomycosis and compared with itraconazole, another triazole which has proven effective in this mycosis. Only 15% of the infected, untreated mice survived while 53 to 75% of the animals receiving itraconazole survived. Mice treated with Schering 39304 exhibited higher (86-100%) survival rates. Statistically, the 5 mg/kg Sch 39304 was superior to the 50 mg/kg itraconazole dose. Lung cultures showed that 20 mg/kg/day of Sch achieved sterilization of the infectious foci. These results indicate that the new triazole will have a place in the treatment of paracoccidioidomycosis.

• Authors: S Restrepo, A M Tabares, A Restrepo
• Journal: Revista do Instituto de Medicina Tropical de Sao Paulo (Rev Inst Med Trop Sao Paulo) 1992 Mar-Apr Vol. 34 Issue 2 Pg. 171-6 ISSN: 0036-4665 [Print] Brazil
• PMID: 1340032 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antifungal Agents
• Triazoles
• Sch 39304
• Itraconazole

Topics

• Animals
• Antifungal Agents (therapeutic use)
• Female
• Itraconazole (therapeutic use)
• Lung (microbiology)
• Male
• Mice
• Mice, Inbred BALB C
• Paracoccidioidomycosis (drug therapy, mortality)
• Survival Rate
• Time Factors
• Triazoles (therapeutic use)